Original Research

DOI: 10.4244/EIJ-D-24-00973

Ticagrelor monotherapy versus ticagrelor plus aspirin in patients with chronic coronary syndrome and high ischaemic risk: a post hoc analysis of the TWILIGHT trial

Mauro Gitto1,2, MD; Usman Baber3, MD; Samantha Sartori1, PhD; Birgit Vogel1, MD; Dominick J. Angiolillo4, MD, PhD; Carlo Briguori5, MD, PhD; David J. Cohen6,7, MD, MSc; Timothy Collier8, MSc; Dariusz Dudek9, MD, PhD; Angelo Oliva1,2, MD; Javier Escaned10, MD, PhD; Yihan Feng1, MS; C. Michael Gibson11, MD, MSc; Ya-Ling Han12, MD, PhD; Francesca Maria Di Muro1, MD; Richard A. Shlofmitz7, MD; Kurt Huber13,14, MD; Philippe Gabriel Steg15, MD; Samin Sharma1, MD; Gennaro Sardella16, MD; Adnan Kastrati17, MD; Upendra Kaul18, MD; Ran Kornowski19, MD; Vijay Kunadian20,21, MBBS, MD; Giulio G. Stefanini22,2, MD, PhD; Shamir R. Mehta23, MD; George Dangas1, MD; Roxana Mehran1, MD

Abstract

Background: Short dual antiplatelet therapy (DAPT) followed by ticagrelor monotherapy may be a valuable therapeutic option for patients with chronic coronary syndrome (CCS) and high ischaemic risk (HIR) undergoing percutaneous coronary intervention (PCI).

Aims: We aimed to compare ticagrelor monotherapy with ticagrelor-based DAPT in CCS patients with and without HIR undergoing PCI.

Methods: The present analysis included the CCS cohort of the TWILIGHT trial, which randomised PCI patients to ticagrelor alone or in combination with aspirin for 12 months after 3 months of ticagrelor-based DAPT. Patients were stratified into HIR and non-HIR based on the 2019 European Society of Cardiology (ESC) CCS guidelines definition. Outcomes of interest were major adverse cardiac and cerebrovascular events (MACCE), a composite of death, myocardial infarction or stroke, and Bleeding Academic Research Consortium (BARC) Type 2-5 bleeding at 1 year.

Results: Of the 2,503 CCS patients who underwent randomisation, the ESC definition classified 1,264 (50.5%) as HIR and 1,239 (49.5%) as non-HIR. HIR patients displayed a higher risk of MACCE (3.9% vs 2.3%; p=0.015) and similar rates of BARC Type 2-5 bleeding (5.1% vs 5.7%; p=0.455) as compared to non-HIR patients. Ticagrelor monotherapy and ticagrelor-based DAPT were associated with similar risks of MACCE (HIR: 4.0% vs 3.8%, hazard ratio [HR] 1.06, 95% confidence interval [CI]: 0.60-1.85; non-HIR: 2.1% vs 2.6%, HR 0.80, 95% CI: 0.38-1.66, pinteraction=0.553) and bleeding (HIR: 4.7% vs 5.7%, HR 0.82, 95% CI: 0.50-1.33; non-HIR: 4.9% vs 6.7%, HR 0.71, 95% CI: 0.44-1.14; pinteraction=0.684) in both the HIR and non-HIR groups.

Conclusions: In a post hoc analysis of the TWILIGHT trial that included CCS patients undergoing PCI, ticagrelor monotherapy after 3 months of DAPT appeared to be safe and was not associated with increased risks of ischaemic or bleeding events, regardless of baseline HIR status, compared with standard ticagrelor-based DAPT. These findings suggest the potential to expand guideline recommendations for ticagrelor monotherapy in CCS.

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 21 Number 10
May 16, 2025
Volume 21 Number 10
View full issue


Key metrics

Suggested by Cory

Clinical research

10.4244/EIJ-D-20-00145 Oct 23, 2020
Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes
Franzone A et al
free

Clinical Research

10.4244/EIJ-D-21-00721 Mar 18, 2022
Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study
Dangas G et al
free

Editorial

10.4244/EIJ-E-25-00015 May 16, 2025
Ticagrelor-based antiplatelet therapy after percutaneous coronary intervention in chronic coronary syndrome
Watanabe H and Kimura T
free
Trending articles
225.25

State-of-the-Art Review

10.4244/EIJ-D-21-00426 Dec 3, 2021
Myocardial infarction with non-obstructive coronary artery disease
Lindahl B et al
free
172.05

Focus article

10.4244/EIJY19M08_01 Jan 17, 2020
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
Glikson M et al
free
80.3

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
47

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved